September 15, 2006 -- A cancer drug from Synta doubled the progression-free survival time in metastatic melanoma patients; GlaxoSmithKline reported that Avandia helped prevent the onset of type 2 diabetes; King Pharma said ramipril, its ACE inhibitor, was not effective against diabetes; Schering and AstraZeneca partnered on a SERD for estrogen dependent cancer; Peregrine announced research that validates its proprietary platform; Genasense from Genta reported positive data against melanoma; Critical Therapeutics said its anti-inflammatory drug candidate failed a Phase II trial; and Pharmion and MethylGene began a Phase II study of a prospective drug for lymphoma. The Centient Biotech 200™ moved 19 points higher to end at 3734.96, an increase of .52%. More details...
